Provided by Tiger Fintech (Singapore) Pte. Ltd.

Legend Biotech

34.84
-0.7200-2.02%
Volume:591.06K
Turnover:20.84M
Market Cap:6.43B
PE:-19.57
High:35.99
Open:35.72
Low:34.84
Close:35.56
52wk High:59.62
52wk Low:27.34
Shares:184.57M
Float Shares:81.38M
Volume Ratio:0.74
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7807
EPS(LYR):-0.9681
ROE:-29.65%
ROA:-7.81%
PB:6.21
PE(LYR):-35.99

Loading ...

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

GlobeNewswire
·
Aug 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 08

Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money

Simply Wall St.
·
Aug 05

Legend Biotech Corporation to Announce Second Quarter 2025 Financial Results

Reuters
·
Jul 28

Legend Biotech (LEGN) Receives a Buy from Goldman Sachs

TIPRANKS
·
Jul 17

Strong Growth and Competitive Advantage Drive Buy Rating for Legend Biotech

TIPRANKS
·
Jul 17

BUZZ-GenScript Biotech jumps on associate's Carvykti sales beat

Reuters
·
Jul 17

BUZZ-U.S. STOCKS ON THE MOVE-Commvault Systems, Rockwell Automation, Tesla

Reuters
·
Jul 17

BUZZ-U.S. STOCKS ON THE MOVE-Legend Biotech, Unity Software, MP Materials

Reuters
·
Jul 16

BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises

Reuters
·
Jul 16

Legend Biotech Reports Strong CARVYKTI® Sales for Q2 2025

TIPRANKS
·
Jul 16

Legend Biotech Reports $439 Million in Net Trade Sales for CARVYKTI® in Q2 2025

Reuters
·
Jul 16

Legend Biotech Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 11

Legend Biotech price target raised to $81 from $80 at Morgan Stanley

TIPRANKS
·
Jul 10

Legend Biotech Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 08

Positive Growth Outlook for Legend Biotech Driven by Carvykti Sales and Strategic Expansion

TIPRANKS
·
Jul 08

Strong Buy Rating for Legend Biotech’s CARVYKTI Amid Limited Competition and Favorable Risk Profile

TIPRANKS
·
Jul 08

Legend Biotech (LEGN) Receives a Buy from RBC Capital

TIPRANKS
·
Jul 08

RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating

MT Newswires Live
·
Jul 07

UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating

MT Newswires Live
·
Jul 03